Introduction
The definitive treatment for patients with lung cancer is in part determined by the clinical staging of the disease. Therefore, it is important that the patient receives an accurate diagnosis of lung cancer and that delay in obtaining correct information on staging of the disease is avoided so that best definitive treatment can be commenced for the individual patient. This is especially important in the management of non-small cell lung cancer (NSCLC), where assessment of the mediastinum is essential to identify operable patients in the absence of extra-thoracic, contralateral lung or pleural metastasis and to determine prognosis. 1, 2 The aim should be that all the required information should be obtained rapidly while performing the minimum number of diagnostic procedures. National Institute for Health and Care Excellence (NICE) guidance for the diagnosis and treatment of lung cancer, therefore recommends choosing 'investigations that give the most information about diagnosis and staging with the least risk to the patient'. 1 Depending on the site of the lesions and ease of access, various modalities can be used to obtain tissue for histological diagnosis.
Endobronchial ultrasound with real-time guided transbronchial needle aspiration (EBUS-TBNA) is a minimally invasive and safe technique that allows systematic assessment of mediastinal nodes to make an accurate diagnosis of lung cancer and other pathology (e.g. Sarcoidosis) and is suitable for subtyping of NSCLC and epidermal growth factor receptor (EGFR) mutation analysis. 3, 4 It is performed as an outpatient under conscious sedation and is well tolerated by patients. 5 NICE has recommended EBUS-TBNA as an initial investigation in patients with enlarged mediastinal lymph nodes and it is expanding as an important diagnostic modality in lung cancer, providing simultaneous information on lung cancer phenotype, genotype and nodal staging. 1 The impact of the introduction of EBUS-TBNA on the use of diagnostic modalities for tissue acquisition in patients with lung cancer is unknown. Therefore, we have investigated the impact of the introduction of EBUS-TBNA in our hospital on other diagnostic modalities for tissue acquisition in patients with lung cancer.
Methods
We conducted a retrospective cohort analytical study of consecutive patients diagnosed with lung cancer at a university teaching hospital in London in 2007, 2009 and 2011. Patients were included for analysis only if they first presented to this hospital (referrals from other hospitals were excluded) and they were validated by comparison with the LUCADA database (National Lung Cancer audit database).
EBUS-TBNA was introduced into routine clinical practice in 2008 and the learning curve was quickly surmounted. 6 Data of 2009 and 2011 are included to demonstrate our change in practice over time following the introduction of EBUS. Data were collected on age, gender, performance status, diagnostic modality and pathological subtype from our electronic patient records and review of case notes. Patients where only a clinical diagnosis was made (n = 12) were excluded. Only the final diagnostic modality was included. For example, if EBUS-TBNA was negative and subsequent tissue diagnosis was achieved by CT-guided lung biopsy, then only the CT-guided lung biopsy was registered as the diagnostic modality.
Data were analysed using StatsDirect statistical software (version 2.7.9). For comparison between categorical variables, 2 or Fisher's exact test were used as appropriate. The unpaired t-test was used for comparison of two continuous variables and the one-way analysis of variance for comparison of more than three continuous variables. All reported P-values are exact two-tailed and are considered statistically significant when P < 0.05.
Results
In total, 316 patients had a histological diagnosis of lung cancer and were included in the analysis. The results on performance status, histological subtype and staging for the 3 years are shown in Table 1 . The results for the diagnostic modalities that provided the tissue for the histological diagnosis of each patient for the 3 years are listed in Table 2 There has also been a trend towards an increased proportion of patients going straight to surgery without pathological confirmation between 2007 and 2011 with a 9.6% (95% CI À0.6 to 19.7%, P = 0.0526) increase in diagnoses obtained at thoracotomy. Furthermore, there has been a reduction in diagnoses of NSCLC-NOS from 10.3% in 2007 to 2.5% in 2011 (P = 0.0216). Table 3 lists the lung cancer staging stratified by the diagnostic modality. EBUS has become the main diagnostic modality for the diagnosis of stage III lung cancer (42.3% increase from 2007 to 2011, 95% CI 25.4-61.2%; P < 0.0001) and for stage IV NSCLC (37.5% increase from 2007 to 2011, 95% CI 25.2-51.7%, P < 0.0001).
Discussion
This retrospective cohort study of consecutive histological diagnoses of lung cancer at a university teaching hospital in London demonstrates the impact of the introduction of EBUS-TBNA on the use of other diagnostic modalities for the acquisition of histological samples in the diagnosis of lung cancer. When investigating patients for suspected lung cancer, it is important to choose an investigation that will provide information on diagnosis and staging to avoid multiple procedures being performed and avoid delays in obtaining the information. Following identification of the site of solitary or multiple lesions on chest radiograph and staging computed tomography (CT), which includes the neck, chest, upper abdomen (liver and adrenal glands) is performed to assist the identification of patients that will be operable and receive definitive treatment with curative intent. Positron emission tomography (PET)-CT is useful to identify inoperable cases by detecting previously unexpected extrathoracic metastases. 7 Furthermore, PET-CT also has a role in evaluating the mediastinal nodes because the sensitivity and specificity of CT in identifying malignant mediastinal nodes is 51% (95% CI 47-54%) and 85% (95% CI 84-88%). 8 Approximately 40% of all nodes thought to be malignant by CT criteria (short-axis diameter of >10 mm) are benign and 20% of nodes deemed to be benign by CT criteria (short-axis diameter 410 mm) are malignant. 9 PET-CT on the other hand has sensitivity and specificity of 74% (95% CI 69-79%) and 85% (95% CI 82-88%) for identifying mediastinal metastasis. [9] [10] [11] However, the sensitivity and specificity of these diagnostic modalities are still low and further evaluation and sampling of mediastinal nodes is required to obtain the correct confirmation of node involvement and to avoid futile thoracotomies. 12, 13 CT and ultrasound-guided biopsies are useful to obtain tissue from peripheral thoracic lung lesions and extra-thoracic metastasis in organs such as the adrenal glands, liver and neck (supraclavicular and cervical lymph nodes but they have limitations due to accessibility of lesions based on location and size, risk of iatrogenic pneumothorax and bleeding and the patient's lung function. 14,15 Bone biopsies are limited by tolerance of the procedure and reduced suitability of samples for genetic testing after demineralization. In our study, from 2007 to 2011, the number of histological diagnoses of lung cancer made by CT-guided lung biopsies remained similar as well as those diagnoses by ultrasoundguided biopsies of peripheral lymph nodes and other extra-thoracic biopsies. Between 18.6% and 23.7% of histological diagnoses were made by modalities that will enable tissue sampling for a histological diagnosis and staging. Mediastinal lymph node evaluation and sampling can be performed surgically with mediastinoscopy, with blind TBNA via standard bronchoscopy or with ultrasound-guided needle biopsy techniques such as EBUS-TBNA. Mediastinoscopy has previously been considered the gold standard method of preoperative mediastinal lymph node sampling, but this is an invasive surgical procedure that requires general anaesthesia, is associated with a 1% complication rate, can not access all mediastinal lymph node stations and has a sensitivity of 78% and falsenegative rate of 5.5%. 2, 16 In approximately half of the cases where mediastinoscopy has been performed pre-operatively in the staging of lung cancer diagnostic tissue, has not been obtained. 17 Mediastinoscopy does, however, allow assessment of extra-capsular spread of tumour and provides the largest mediastinal lymph node biopsy samples. EBUS-TBNA allows sampling of paratracheal, subcarinal and hilar lymphadenopathy under conscious sedation in the outpatient setting and is well tolerated by patients. 5 It has high sensitivity of 90% and specificity of 100%, negative predictive value of 83%, positive predictive value of 100% and diagnostic accuracy of 93% even early in the learning of the technique. 6 In the investigation of isolated mediastinal lymphadenopathy it resulted in the avoidance of mediastinoscopies for tissue acquisition in 87% of cases and had sensitivity and negative predictive value of 92% (95% CI 83-95%) and 40% (95% CI 12-74%), respectively. Interestingly, in our centre more patients over time are being referred directly to surgery without pre-operative confirmation of the histological diagnosis, demonstrated by the trend towards an increase in histological diagnoses made from thoracotomy biopsies from 12.4% in 2007 to 22.0% in 2011. However, the number of video assisted thoracoscopic surgery (VATS) biopsies remained similar throughout the study period. This increase in direct referrals for thoracotomy may be due to suspecting lung cancer at a stage where patients are still fit for surgery as demonstrated by an improvement in mean performance status between 2007 and 2011, but, as demonstrated in Table 3 , the increase in thoracotomies is not due to the increase in diagnosis of disease at an earlier stage.
We are now in an era of personalized medicine, where novel and targeted specific therapies (e.g. EGFR antagonists) are used in the treatment of lung cancer, sufficient and good quality tissue samples need to be obtained. EBUS-TBNA enables sample acquisition for histological diagnosis, immunohistochemistry, mutation analysis and nodal staging, all in one single intervention and its use is increasing. The use of immunohistochemistry has been shown to reduce the NSCLC-NOS. 4 This reduction in diagnoses of NSCLC-NOS from 10.3% in 2007 to 2.5% in 2011 was also seen in this study.
The limitation of this study relates to its retrospective nature, which means that only patients who were clinically selected for each diagnostic modality (including EBUS-TBNA) were included. However, consecutive patients were included to minimize this bias. As these data represent the service of a single centre with expertise in EBUS-TBNA, the results may not be generalizable to all institutions but these results may assist the commissioning of services in centres implementing their own EBUS service.
This study demonstrates that the introduction of EBUS-TBNA has resulted in significant changes to the number of histological lung cancer diagnoses made by the different diagnostic modalities. Although we did not assess the exact number of procedures that were conducted over this time period, we infer that there has been a significant reduction in number of standard bronchoscopies and mediastinoscopies. This may, in the future, have an impact on the training of respiratory medicine and cardiothoracic surgery specialty trainees. Furthermore, more patients are having EBUS-TBNA and despite there being evidence that it is cost saving in patients with isolated mediastinal lymphadenopathy, 18 it is unclear what the cost implications will be in lung cancer staging. Additionally, further studies will need to identify if this has an impact on patient experience.
Conclusion
The use of diagnostic modalities that provide information on diagnosis and staging in a single intervention are increasing. At our institution, the use of EBUS-TBNA for providing a lung cancer diagnosis is increasing and this has led to a significant reduction in standard bronchoscopies and mediastinoscopies. These changes in practice may have implications for future service provision, training and commissioning.
